Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 5/20 | 0.40 |
| ▸ | HINT1 | P49773 | 5/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913296 | 0.87 | POLB (0.51) | POLBKRASP2RY2P2RY4P2RY6 | |
| SCHEMBL21786806 | 0.86 | POLB (0.46) | KDM4EPOLBHINT1HPRT1P2RY2 | |
| SCHEMBL21787181 | 0.86 | POLB (0.39) | POLB | |
| SCHEMBL21787189 | 0.83 | POLB (0.47) | KDM4EPOLBHINT1HPRT1P2RY2 | |
| SCHEMBL24913494 | 0.83 | POLB (0.47) | KDM4EPOLBHINT1HPRT1P2RY2 | |
| SCHEMBL24913351 | 0.82 | POLB (0.47) | POLBKRASHPRT1P2RY2P2RY4 | |
| SCHEMBL21786914 | 0.81 | POLB (0.48) | KDM4EPOLBHINT1HPRT1P2RY2 | |
| SCHEMBL21786870 | 0.81 | POLB (0.48) | KDM4EPOLBHINT1HPRT1P2RY2 | |
| SCHEMBL21786838 | 0.81 | POLB (0.37) | POLBP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL21787087 | 0.81 | TK1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | KDM4E 3593/4885POLB 12/4885KRAS 1112/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | KDM4E 3595/4885POLB 11/4885KRAS 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.